|
مقاله
|
Abstract
|
|
|
Title:
|
The Effect of Bevacizumab (Avastin®) on Posterior Capsular Opacification after Phacoemulsification: A Randomized Clinical Trial.
|
Author(s):
|
Mansour Rahimi, Mohammad Reza Talebnejad, Gholam Abbas Roustaei, Mahnaz Mosallaei
|
Presentation Type:
|
Poster
|
Subject:
|
Cornea and Anterior Segment
|
Others:
|
|
Presenting Author:
|
|
Name:
|
Mansour Rahimi
|
Affiliation :(optional)
|
Poustchi Ophthalmology Research Center, and Ophthalmology department, Shiraz, Iran.
|
E mail:
|
mrahimi@sums.ac.ir
|
Phone:
|
|
Mobile:
|
09171117869
|
|
|
Purpose:
|
The aim of this study is to evaluate the possible effect of Bevacizumab (Avastin) on prevention of posterior capsular opacification after phacoemulsification.
|
Methods:
|
Sixty-eight patients were included in the study. Inclusion criteria were senile cataract and exclusion ones were history of diabetes mellitus, cardiovascular, cerebrovascular or thromboembolic disease and ocular pathologies. Patients underwent phacoemulsification and equal numbers of them were randomly assigned to either receive intracameral bevacizumab (ICB) 1.25 mg/0.05 ml or BSS as control. Digital retroillumination of the posterior capsule obtained 2 months and 1 year postoperatively. Image processing and calculating PCO score were done using an Objective System Capsule Analysis (OSCA).
|
Results:
|
At 2 months, a mean OSCA PCO score of 0.45061 ± 0.22419 was found for the ICB group and a score of 0.46449 ± 0.30933 was found for the control group. At 1 year, it was 0.78390 ± 0.15707 for the ICB group and 0.90807 ± 0.37180 for the control group. There were no significant difference of the mean OSCA PCO score between two groups at 2 month and 1 year postoperatively (p = 0.86 and p = 0.16 respectively). No patient underwent Nd: YAG laser capsulotomy during follow-up period.
|
Conclusion:
|
This is the first study on possible effects of bevacizumab on PCO. Although 1 year PCO score at the ICB group was less than control, the difference was not statistically significant. This lack of difference may be either due to shortness of follow-up or infectivity of intervention.
|
Attachment:
|
688Dr. Rahimi Poster.pptx
|
|